文字稿 🔗
0:00
When the United States government decides to invest major funds in a new longevity therapy. It's time for us to pay attention. when you're developmental jazz. Shonibare presented his work to the National Institute of Health. His vision sparked so much enthusiasm, so much confidence that the NIH decided to grant him an exceptional opportunity to turn it into reality and to help and get there within just five years. what makes John Vision so groundbreaking that the US government is willing to bet on it. Stay tuned to find out how this work could revolutionize human health and extend human lifespan within our lifetime. So just to pick up where we left off body replacement, we talked about several options. So I was curious if there is any direction or combination you're leaning toward more than others. And what seems most feasible to you right now? Yeah. So as you mentioned, there's all different approaches one can take to replacement to reverse, you know, age related damage either. Piece by piece sort of approach and either synthetic replacement parts or biological ones. It's a little harder for me to assess the synthetic ones and how close they are to in general to being applied in the clinic, although some are already in the clinic. You know, we have artificial hearts. Still room for improvement there. But, you know, so there's bioreactor kidneys that at least one group is working on that you know could could reach the clinic before too long. So there are component parts. And then of course, there's, you know, a group that has kept brains alive with completely synthetic organ replacements, if you like, so circulating blood's filtering system, etc., that could potentially, you know, and in the long run, replace biology altogether. But that's the extent of what I know. So I'm not like a real expert at assessing how close those synthetic approaches are biologically. You know, I think we could be very close to replacements. The brain, of course, is very challenging. That has to be done progressively if you're going to replace substantial parts of the brain or the entire brain. So there's still a lot of work to be there to be done there. But, you know, we do have a roadmap for getting there. The body, you know, I mean, conceptually, the simplest way and I believe technically the simplest way is to replace the whole body with a new body. Of course. Where do you get that? Body has been a problem. There are some who you know are those that are, you know, brain dead. Could be a source. I know there's there's interest there in using bodies from young brain dead individuals to save the lives of others who have, like complete degenerative conditions or life threatening conditions, which makes sense, you know. But then the other source of potential bodies is to grow them. But of course, you have to grow them without a brain or else they're a person. And so you can't just be taking bodies from people. And so that would be another way. But technologically
Load full transcript
that, you know, we know how examples of how that's done in preclinical models sort of every step of that approach. So that's the most straightforward one, is just replace everything at once. Whether the public in general will be immediately receptive to this or not, you know, we'll have to see. But, you know, that's something that I think could definitely work. Whereas the piece by piece, organ by organ, body part by body part, you know, that's a lot more surgeries. Of course, that can work. But, you know, with each surgery comes complications, risk of complications. And so and also the timing, you know, how quickly can you do this before, you know, a young organ succumbs to failure because the surrounding body is failing. But, you know, I guess you could do it at a pace where it should still be fine. You know, again, we do that already for organ transplants, Right? We and we don't take typically old organs into young bodies. You know, what's favored is to take a younger, healthier organ into an older body, or at least the equivalent age body. So so this is already being done. But in those cases, it's either a very generous person giving up one of their kidneys or, you know, again, brain dead donors. Yeah. Yeah. Or order! Order your new body on Amazon. I'm not not there yet, but yeah, it's a nice idea. Yeah. One day. Yeah, yeah. Especially since, again, the body is super complex and the way the body ages is just, like, more complex. Like everything's going raw and in, in a myriad of ways. So yeah, if we have to understand everything that's involved in aging well, I don't know if we'll ever get there. So, yeah, it's replacement. You don't need that. Get rid of all the damage all at once. And I wanted to to take a little like terminology break to just clarify some things, because last time we talked about you, you want to extend the maximum lifespan not only in the median lifespan, which I think not everybody fully understand what it means. So maximum lifespan hasn't really changed, right? It's around maybe 115 years. And when we talk about increasing lifespan that we've seen along the years, this is median lifespan. It has been increased, meaning more of us live longer thanks to hygiene and medicine and etc.. And you say that mainstream longevity approaches today won't impact maximal lifespan because they don't impact aging, meaning they will only maybe improve median lifespan by improving health. but I and you say that this is what medicine has kind of always been doing that in that sense, that's nothing new. But I was wondering about that because I always thought there is like a really dramatic paradigm shift in the longevity field as a whole, which says like, okay, let's target the underlying mechanism, not the diseases themselves, but the underlying mechanism like the hallmarks of aging, if you will, so we can have a better response to age related diseases and conditions and which I interpret is is like, okay, so it will maybe allow us to fulfill that potential of the max, like live up to the limit, but in good health. So maybe we will gain 30 more years of good health and functionality is do you see it that way? And if so, don't you think it's kind of also a big deal and worthy of pursuing of course. You know, anything that adds time and quality of life to our lifespans is worth pursuing. And so definitely increasing health and longevity in that sense is definitely worth pursuing. I think the definitions between, you know, average and maximum lifespan are still important to keep in mind in being clear about what the goal of the approach is. So some approaches, you know, I would argue based on what we know about the biology and the science behind them will potentially their proof is in the pudding, will potentially increase health without any evidence that they will slow the aging process per say, allowing more of us to get to closer to, you know, 90, 100, 110. If you're a real outlier. And that's great, you know for sure, let's do that. But I guess the distinction between average and maximum is important with respect to aging, because in those cases, I think you're just really increasing health and not going, you know, going to go beyond the maximal lifespan. And that's where the confusion arises, is a lot of people think that if you're increasing health and longevity, that you're slowing aging. It's it's it's used all the time. And if you're slowing aging, you would necessarily be extending maximal lifespan. And I think that's a little misleading terminology to say that you're slowing aging when really you're just getting or working on the possibility of being healthier as we nevertheless age. So for me, it's an important distinction because I would like us to have, you know, a lifespan that's determined by us, not by our failing bodies, no matter how healthy we are. You know, we hit that precipice at at around 100. And and yeah, you know, even the healthiest 98 year old has a very short life expectancy, unfortunately. And that, you know, and if you're looking at the brain, no matter how sharp we think they are and there's a lot of variability between individuals, if you test them rigorously, they're still way below what they were when they were younger. But do you see a distinction between how medicine is today and where where it's going in terms of addressing that problems differently? Is that a shift that needs to happen in medicine, or do you just see it as an extension of kind of the same thing? I see that there is a shift that needs to happen there if we're to live significantly longer and healthy like, you know, well above 100 or indefinitely, if that's what, you know, individuals choose to do. I think there needs to be a shift in thinking there Yeah, I guess what I'm saying is that like medicine today is not even on board with the longevity, the type of longevity science that you criticized. Right. It's not it hasn't really embraced even that. yeah. So, I mean, a lot of
the leading candidates, you know, like metformin and rapamycin, I think the health field in general, you know, is not too enthusiastic about their heads because the evidence doesn't really support enthusiasm. So I don't think they're it's a, it's a they're not even at that point where they need to think, do we want to do this? Because it's still at that point where these things aren't going to have a big impact. So they don't even need to think about it, you know? So and there are plenty of examples like that, treatments that either there's no real evidence yet that they can have a significant impact in terms of maximum lifespan or even average lifespan. So we can certainly try to get people to be more aware in general in the health care industry and the population at large, just so that when we do get there, they'll be like, finally, as opposed to, we don't want this. Ironically, that can be reassuring to people who are really afraid that the longevity field will like will be like sci fi, radical, like life extension and immortality. And like, it doesn't seem like it's most of the field is going that way from what you're saying. Although I just saw a post where they said that they didn't know David Sinclair published something that, Alzheimer's symptoms were reversed with in mice with like cellular reprograming. So that's kind of I think I guess what I'm imagining is, okay, we're not going to break the limit of the maximum lifespan, but maybe we're going to curb some diseases yeah, life better. yeah, maybe. Although, you know, that's a claim that in the field we've heard, you know, maybe at least 50 times, you know, we've reversed Alzheimer's and then Okay, so where is it In the clinic. Not there. Okay. Yeah. No. So arpa h I guess is an opportunity that I couldn't say no to because unlike the rest of the NIH, they're really looking for big, ambitious projects like, you know, functional cortical tissue replacement, which is close to my heart, but other lots of other projects as well that might be of interest to people who want to live longer. And so there's quite a variety of projects that are being worked on there. So, yeah, I mean, what I've been doing in my lab, you know, progress is very slow. We've we've been interested in functional cortical tissue replacement in my academic lab. And then I started a company and we were working on that, making progress. But again, it's a big project and there's a lot of work to be done. And ARPA h is an opportunity for a type of project like this to make it to the clinic in, you know, a much shorter time than it would otherwise. this is interesting because last time we talked about how the FDA isn't as conservative as maybe I thought it was and to see a government agency embrace such a project. did it surprise you a little bit. Yes, not so much, because I think the FDA has any issues with the type of technologies we talk about when we talk about replacement. But just because my you know, my decades of experience getting an AI age grads that have taught me that they tend to be a little bit conservative about what they find generally. And I thought, you know, something like sort of the pro gram that I submitted as a proposal as part of my application was, you know, to achieve functional cortical tissue replacement and I didn't think they'd go for it, and they did. And so I'm very pleasantly surprised by that. And I was even encouraged to be bolder in my proposal than I was. I you know, I was I think I was suggesting a, you know, a proof of principles or showing that that neurons in new tissue that was put there by by whatever means ends up putting it there, that those new neurons underlie a useful part of a re acquired behavior. So they actually encode information that's useful to their hosts. So I was suggesting, you know, that that be the goal in five years. And they were like, well, you know, why not be in the clinic in five years? All right, I like you. I like you guys. Yeah. So yeah, exactly. Yeah. So it's just the mindset that they have is to think big, think bold, make a difference, you know? So, yeah, that's very exciting. And is it working on strokes at this point, or am I confusing it with something else yeah. So, I mean, permanent brain damage occurs from many different causes. Aging, but also strokes, traumatic brain injury, degeneration, resection of tumors, sometimes infections like there's a lot of different causes and sometimes we don't know what the causes like. Well, in cases of degeneration, for example, and there's really none of them have any effective treatments when there's permanent brain damage. And so, you know, if if we do get a program on functional cortical tissue replacement that could potentially address any one of those forms of damage. But you have to start somewhere and sort of be the one that makes the most sense because it's localized damage. It's super common in the population. So you have no, you know, lack of potential patients. You can also be very selective about the patients in terms of size of stroke and location of stroke. So, you know, just stroke makes the most sense as a as a first test for whether you can get functional tissue replacement. Yeah. Yeah, yeah. If we had unlimited funding, again, the technological advances, the brain being the most complicated and having the higher risk of running into unexpected, you know, hurdles that we need to deal with. But the approach is, you know, again, I mean, not conceptually straightforward in terms of recapitulating normal development. And we can we can get high resolution information about how normal development occurs, you know, with single cell omics and looking at extracellular signals and everything we can, we should be able to reverse engineer normal brain development without too much problem following the normal blueprint of how it happened in the first place. In the first place. But that is the most complicated thing. So you know how long that will
take, I guess, you know, we'll see in next five years if we can get to the clinic. I think that's a little ambitious, though, even though that's going to be probably the proposal. But I'm game. I'll do everything I can to make that happen. But, you know, maybe it takes another five four for that for for the body. You know, I think, again, the technological advances required or not, there's not that novel. I mean, there's really the technology already exists and just has to be adapted to that approach. So that's that's more a question of, you know, when when do we want to do it? I know there's some working on this already. They're making progress, but, you know, there isn't much funding for that. So if we decide to or if we have unlimited, you know, all the money in the world, I think they could easily get there in a short time, like years. Yeah. And do you see, does a AI impact your work in any way? Are you optimistic about that? right now, not so much, but I hope more and more that it will not in the sense of, you know, finding solutions because unless we come up with AGI or, you know, super AI that can think and learn on its own because right now a lot. Okay, yeah, I don't know. I hear mixed numbers but yeah but then that could maybe that, that could be helpful in ways that I can't predict. Right. If I could learn on its own and be smarter than us, then who knows? But, but with you know, AI that needs lots of data to learn it. You know, we don't have lots of data to give it. We're we're generating the data every day is small amounts. So it's not something that the AI of today can make good use of to guide us or help find solutions moving forward. But that's not the only thing I is used for. A.I. is used for lots of other things that could be very helpful, like robotic automation, robotic surgery or analysis. A lot of analysis that we do in the lab now is very labor intensive and is not currently easy to automate because of just variability in different factors. Although if a human is looking at it, we know what is, you know, not is just like junk or like if you're doing a staining of a tissue, histologically, you know, you know that that part of the tissue is ripped or, you know, degraded so you don't even bother looking at it. But that's very difficult with current levels of automated analysis to make sense of. But I could do that so I could help with a lot of analysis of sort of that raw data or computational data. And again, you know, sort of robotic A.I. for repetitive tasks that there's still a lot that we do by hand. And then hopefully surgery will be in improved. I know there's a lot of interest in that and developments there that I that I wasn't aware of until recently. But, you know, the state of the art of state of the art is progressing nicely for surgical robots. So I hope that continues. Yeah. So I you know, as of not that long ago, I used to say that there's enough talent around. We just need the money to recruit it. Now, I'm thinking maybe there's not enough talent around now that we have significant potentially significant resources to start addressing that. So I would encourage people to consider, you know, some of the skill sets that are needed and the replacement technology that we're building, particularly for the brain. So sort of neurodevelopment background. So an understanding of how the brain normally develops, is this really helpful? You know, neurophysiology, stem cell and everything in between. Those are all areas where I hope there won't be a shortage of talent. But, you know, I think we could still use more. That's interesting that until now we couldn't really know because there wasn't enough money to pay all the talent and now you see that there is a limit to the talent Yeah. people would like to support this effort, how can they do so? What are the ways to help help make this happen? Yeah. I think, you know, there's still, even with the HiRISE and of much more resources from the government, you know, there's still an opportunity there for anybody who wants to invest, you know, it's actually a great time to invest in these kinds of approaches, given that there's potentially this big wave of support coming. But also, yeah, just what we were talking about now, talent making people aware that there's likely to be opportunities in this sector that open up. be aware of that. Yeah. Do you know? Is there anyone else working of, brain tissue replacement? Yeah. So, you know, I've been encouraging lots of people to start like new companies on that and you know, to be aware that B Therapeutics is still around. So, you know, there there are efforts and I hope a growing number of efforts and if anybody's really interested, they should reach out to me and I can connect them with the relevant people. Yeah, Yeah. I think conceptually there there is a lot of overlap in, you know, use being guided by normal development to get the the right cell types, the right structure and the right wiring to occur. But in each part of the brain, there are different cell types, there are different structures and the wiring is different. So, you know, as soon as you get into the details that are different, so the developmental pipeline can be similar, but the details are different. so, so yeah, so that sounds like if, if, if, if people have interests in that, that's still something that needs work yes, lots of work. Yeah. Yeah, I yeah, yeah. But I will keep encouraging people and yeah, you know, if you want to spread the word, that'd be great. just a bonus question with all the buzz that's been around lately in kind of pop culture about you've probably heard of Blueprint, Brian Johnson and there was this show and LTD with Peter Attia. People got really excited about all this. How do you view it? Do you think it's helpful and helpful? what do you think about this phenomena? Yeah. This is an example where I think it's important to be clear so that people aren't misled. I think what they're doing is great for health and you know, there's probably a lot of great tips there about how to be healthier, but I don't think anything that they're doing is slowing down aging maximally healthy people. There have been people in the past who've done all the right things, exercised, you know, into their nineties, eaten well, gotten good sleep, you know, all that stuff. And the whole time they age, this doesn't impact aging per se. So as long as we're clear about that, I think it's wonderful that people want to be healthier longer. And yeah, they should everything they can to to do that. yeah, yeah. And I totally agree. And that's why I think it's important not to have misconceptions about what can be achieved with these approaches. Yeah, Do you have any last stats or were there any, any, any, anything major that I missed? I know that we spoke quite, kind of generally, but, yeah, yeah. No. All good. You know, maybe one thing I wanted to say was, you know, thank you for being part of this building awareness and interest in using, you know, some more innovative approaches to living much longer, you know, beyond maximal lifespan and also being healthier. Yeah. yeah. Well, thanks for giving me a voice. thank you so much. And we're. I'm already going to schedule another talk for five years from now, Very. Yeah, me, too. Yeah,